email article
More than half of patients with steroid-refractory hand eczema responded quickly to a pan-Janus kinase (JAK) inhibitor in a randomized, placebo-controlled trial.
After 16 weeks of treatment, patients treated with the higher of two doses of gusacitinib had a 69.5% reduction in target lesion symptom score (TLSS), as compared with 49% among patients randomized to the lower dose of the drug, and 33.5% of placebo-treated patients. Response to gusacitinib occurred as early as 2 weeks after the start of treatment.
The higher dose of the JAK inhibitor led to a 72% improvement in the Hand Eczema Severity Index (HECSI) at 16 weeks, as compared with 20.8% in the placebo arm, reported Howard Sofen, MD, of Dermatology Research Associates and the University of California Los Angeles, at the American Academy of Dermatology virtual meeting.